Video Experimental Relacionado
Updated: Mar 3, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Evolocumab añadido a las estatinas para reducir la progresión de la aterosclerosis coronaria
Stephen J Nicholls1, Ransi Somaratne2, Steven E Nissen3
1South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia.
No abstract available in PubMed .
Más Videos Relacionados
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
08:02Author Spotlight: Enhanced Quantification of Cardiovascular Calcification Progression for Longitudinal Micro PET/CT Studies in Small Research Animals
Published on: November 15, 2024
Videos de Conceptos Relacionados
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Cholesterol: Significance and Regulation
Considering cholesterol and...
Atherosclerosis IV: Nursing Management
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...